The Benefit Of Having A Highly Engaged Editorial Advisory Board
One of Life Science Leader’s newest editorial advisory board (EAB) members is Pamela Reilly Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics....
31 July, 2020
News & Events
16748page-template,page-template-blog-masonry,page-template-blog-masonry-php,page,page-id-16748,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
News & Events
A Small Biopharma’s View Of Working With CROs
Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services....
01 July, 2020
BioEclipse Therapeutics™ Announces Move to New Corporate Headquarters in Mountain View, CA
BioEclipse Therapeutics™ today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Collaboratory, a 104,000 square-foot facility in Mountain View, CA. ...
19 May, 2020
BioEclipse Therapeutics — More Than Just A Story Of Rebranding
In 2006, Contag cofounded ConcentRx (pronounced concen-tricks), but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. When asked about the details of what transpired between those 10 years, Contag was extremely transparent, sharing not only her frustrations but the wisdom she earned throughout this unusual business journey....
01 May, 2020
BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100
BioEclipse Therapeutics™ announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for the Company’s lead drug candidate, CRX100....
28 April, 2020
BioEclipse Therapeutics™ Announces Appointment of New Directors and Series A-1 Financing
BioEclipse Therapeutics™ today announced that it has raised $7.7 million in its Series A-1 financing round, which was led by Revelis Capital Group, LLC and managed by VENTURE.co Brokerage Services, LLC, with participation from Tsingyuan Ventures, DEFTA Partners, TSVC (TEEC Angel Fund) and Plum Alley. BioEclipse has now raised a...
24 June, 2019
BioEclipse Therapeutics Honored by Goldman Sachs for Entrepreneurship
BioEclipse Therapeutics™ today announced that Goldman Sachs has recognized BioEclipse Co-Founder & CEO, Pamela R. Contag, Ph.D., as one of the 100 Most Intriguing Entrepreneurs of 2018 at the seventh annual Goldman Sachs Builders + Innovators Summit in Santa Barbara, California....
18 October, 2018
BioEclipse looks to synergistic therapies to topple stubborn cancers
For the last 20 years, Pamela Contag has studied cancer. And in that time, the world’s understanding of cancer has changed dramatically. “I remember when people were saying ‘One gene, one protein,” which we now know is wrong,” she told Drug Delivery Business News....
09 August, 2018